Understand the source comparison
Neuroinflammation Suppression vs Neurogenesis Support — Mechanism Specificity
The mistake most brain aging protocols make is treating all peptides as interchangeable 'nootropics.' They're not. Some peptides suppress inflammatory cascades; others stimulate new neuron formation. The distinction matters because the pathology you're address
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The mistake most brain aging protocols make is treating all peptides as interchangeable 'nootropics.' They're not. Some peptides suppress inflammatory cascades; others stimulate new neuron formation. The distinction matters because the pathology you're addressing determines which mechanism provides benefit.
- Chronic neuroinflammation. Characterised by elevated microglia activation and cytokine release (IL-1β, IL-6, TNF-alpha). Is the primary driver of age-related cognitive decline in individuals without overt neurodegenerative disease. Research from the University of Cambridge found that elevated IL-6 levels in cognitively normal adults predicted 3.2 times higher risk of cognitive impairment within 5 years. Peptides like Thymalin (thymus-derived peptide) directly modulate microglial activation, reducing pro-inflammatory cytokine secretion by 40–60% in preclinical models.
- Thymalin's mechanism involves T-regulatory cell activation. It enhances the function of immune cells that suppress excessive inflammatory responses. A clinical trial in older adults (mean age 68) found 10-day Thymalin administration reduced circulating IL-6 by 35% and improved subjective cognitive performance scores. That's not placebo response. It's measured immune modulation translating to reduced neuroinflammatory load.
- Contrast that with Cerebrolysin, which operates through neurotrophin receptor activation. It doesn't primarily target inflammation; it supports neuronal survival and dendritic complexity in existing cells. The benefit accrues in individuals with measurable hippocampal atrophy or synaptic loss. Not those whose primary pathology is inflammatory.
- Dihexa is purely synaptogenic. It stimulates new synapse formation through HGF receptor binding. This matters in contexts where synaptic density has declined but neurons remain viable. Post-stroke cognitive impairment, mild cognitive impairment with preserved hippocampal volume, and age-related executive function decline all represent conditions where synaptogenesis offers measurable benefit.
- Our experience working with research-focused protocols shows that combination approaches targeting both inflammation and neurogenesis produce the most consistent cognitive preservation. Thymalin + Cerebrolysin, or P21 + Dihexa. One compound addresses the loss pathway while the other supports the growth pathway.